Betalutin slår knock out på Copanlis/Bayer med CR 44% mot 13%

SomSa
NANOV 27.06.2019 kl 13:54 15489

Bayer eier Aliqopa (copanlisib)

JUNE 20, 2019
Aliqopa (copanlisib) Granted FDA’s Breakthrough Therapy Status for Previously Treated Marginal Zone Lymphoma
https://lymphomanewstoday.com/2019/06/20/aliqopa-granted-fdas-breakthrough-therapy-status-previously-treated-marginal-zone-lymphoma/


12 June 2019
COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

Results: The 23 MZL patients enrolled included 15 (65%) nodal MZL and 4 each (17%) with mucosa‐associated lymphoid tissue (MALT) lymphoma and splenic MZL.
Objective responses by independent assessment were observed in 18 patients (ORR 78%) and CRs in 3 patients (13%);
ORRs were 50% (2/4 patients) in MALT MZL, 87% (13/15 patients) in nodal MZL and 75% (3/4 patients) in splenic MZL.

https://onlinelibrary.wiley.com/doi/10.1002/hon.69_2631


Betalutin´s resultater for Marginal zone lymphoma (antall pasienter 9): ORR 78% og CR: 44%

Nano side 9:
http://www.nordicnanovector.com/sites/default/files/Stockholm%20May%202019.pdf

Det blir PIM i UK!
Redigert 22.02.2021 kl 09:32 Du må logge inn for å svare
Slettet bruker
22.02.2021 kl 19:20 3293

Helt sykt kan gå høyt nå
Sitter long
bj111
22.02.2021 kl 19:32 3227

Er det ikke de som drev Algeta som startet NANOV? Hvis det er tilfellet så vet Bayer meget godt hva de er kapable til og det er kun et spørsmål om tid før NANOV blir slukt av Bayer. Prisen er det som blir spennende å se her.
Bullinvestor
22.02.2021 kl 20:02 3078

Det stemmer mange av personene som satt i Algeta sitter i Nano nå. Tror erfaringen Nano ledelsen sitter på kan bli gull verd. Spent hvor vi er kursmessig om 2-3 uker: )
Londonmannen
22.02.2021 kl 20:12 2999

Ja, den som visste det. Men vi bommer vel ikke mye dersom vi tror at 30-tallet er historie. Men nå når katta er sluppet ut av sekken, og flere kan komme, så er det helt umulig å spå hvor denne går på to til tre ukers sikt. Vi får bare nyte oppturen.
SomSa
22.02.2021 kl 20:31 2878


Mest spennende blir kommende kliniske data fra Betalutin (177Lu-satetraxetan-lilotomab) + rituximab (RTX) for andre linje bahandling (2L FL). Pasientgrunnlaget er mye større. Med gode data kan aksjen være 50-80 og vi må håpe på at de henter 500 -1000 mil på kurs 35-70.
Slettet bruker
22.02.2021 kl 20:50 2787

Archer og MZL.data kommer mars april ingen emisjon for dette blir presantert.
Panis
22.02.2021 kl 20:56 2738

Det er ikke bare de som «drev» Algeta som er i Nano, men det er serie grunderene Roy Larsen og Øyvind Bruland som har startet både Algeta, Nordic Nanovector og den siste Oncoinvent. Alle med veldig gode resultater innen sitt segment. Så de er hovedgrunnen til at jeg gikk inn i Nano og Oncoinvent.

https://www.nettavisen.no/na24/superaksje-har-gatt-fra-13-til-120-kroner-pa-ett-ar-gr-nder-roy-larsen-tror-det-bare-er-starten/s/12-95-3423290976

https://finansavisen.no/nyheter/helse/2020/05/18/7529188/pe-fond-inn-i-kjendistungt-kreftmedisinselskap
Redigert 22.02.2021 kl 21:05 Du må logge inn for å svare
bj111
22.02.2021 kl 21:00 2698

Nettopp og nå ser det ut til at de vil lykkes igjen. Er iallefall ganske skyfri himmel slik det nå ser ut. De som hopper av er vel de samme som hoppet av på 20 kroner i Algeta for så å løpe etter.
Start
22.02.2021 kl 21:57 2494

Blir vel emi her.fri for pæng.
SomSa
12.11.2021 kl 14:46 1475


Har noen hørt eller er diskutert om dette, er det samme pasientgruppe som NANO behandler?

September 9, 2021
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Preliminary efficacy results reported in the trial were 88 percent overall response rate (ORR) and 38 percent complete response (CR) in patients with relapsed/refractory DLBCL who received the RP2D of 48mg of (n=8) epcoritamab.
Patients who were treated with 12-60mg of epcoritamab (n=22) achieved a 68 percent ORR and 45 percent CR.
Additionally, patients with relapsed/refractory FL treated with 0.76-48mg of epcoritamab (n=10) achieved a 90 percent ORR and a 50 percent CR

https://news.abbvie.com/news/press-releases/clinical-trial-investigational-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsedrefractory-b-cell-non-hodgkins-lymphoma-b-nhl-published-in-lancet.htm
Redigert 12.11.2021 kl 14:46 Du må logge inn for å svare
Falketind
12.11.2021 kl 16:03 1343

Jeg tenker at dette finner du godt svar på selv (SomSa). Antar at du allerede har svaret som passer med din egen oppfatning 🤔.
Merlin
12.11.2021 kl 16:09 1313

SomSa, hvorfor lager du ikke en sammenligning med Archer-1 ORR 100% CR 70%?

Update from Archer-1 Phase 1b Trial of Betalutin® in combination with rituximab in 2L Follicular Lymphoma
TUE, MAY 25, 2021 07:00 CET
Oslo, Norway, 25 May 2021

Nordic Nanovector ASA (OSE: NANOV) announces initial promising data from the Archer-1 Phase 1b trial investigating Betalutin® (177Lu lilotomab satetraxetan) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL).

The preliminary results show clinical activity with seven out of seven patients achieving a response, including 5 complete responses and 2 partial responses. All responses are currently ongoing, 5 of them 2 years after Betalutin® administration.

Across this patient group, Betalutin® with RTX showed a very good safety profile, comparable to that of single agent Betalutin®, with no dose limiting toxicities observed.

Archer-1 is a Phase 1b open-label, single-arm, multi-centre dose-escalation trial to assess the safety and preliminary activity of CD37-targeted Betalutin® in combination with CD20-targeted RTX in patients with relapsed/refractory FL who have received one or more prior therapies.

The starting doses of Betalutin® and lilotomab were 10MBq/kg and 40mg, respectively, which was escalated to Betalutin® 15MBq/kg and lilotomab 40mg in the second cohort. Following Betalutin® dosing, patients received four weekly doses of RTX (375mg/m2) on days 7, 14, 21 and 28. Patients who did not progress (including CR, PR, SD) were scheduled to receive RTX maintenance for 2 years.

The primary objective of the study was to evaluate the safety and tolerability of Betalutin® in combination with RTX, the secondary objective to evaluate the preliminary anti-tumour activity of combination treatment.

The rationale for Archer-1 was provided by earlier preclinical data showing Betalutin® can up-regulate CD20 expression in different rituximab-sensitive NHL cell lines and act synergistically with rituximab in a rituximab-sensitive NHL animal model and, more recently, that Betalutin® has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma models.

Peter Braun, Nordic Nanovector CEO, commented: “We are encouraged by the results in this small Phase I study in second line FL patients. Both the overall safety of this combination and the preliminary signs of efficacy are promising. We look at this study as an additional building block in our overall strategy to develop Betalutin® for difficult to treat hematological tumors. Our near-term focus remains very much on completing PARADIGME in 3L FL and delivering top line 3-month data by the end of 2021.
Redigert 12.11.2021 kl 16:10 Du må logge inn for å svare
AksjeInvest
12.11.2021 kl 17:03 1167

Boooom og burn på en gang! :)